Version May 2024
Note: A skin test should be performed 4 weeks prior to treatment. Refer to the manufacturer's instructions for use for additional information on the interpretation of skin test results.
Nasolabial folds and facial acne scars: Intradermal: ≥21 years: Inject as needed for cosmetic result; injecting >3.5 mL per treatment site or 8.9 mL overall has not been established. Correction should be limited to no more than 100% of the skin defect during treatment. One or two touch-up implantations at intervals of at least 2 weeks may be required to achieve the desired effect.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences reported with acne scar treatment unless otherwise indicated.
1% to 10%:
Central nervous system: Fatigue (1%)
Dermatologic: Contact dermatitis (1%), pruritus (nasolabial fold [NLF] and acne scars: ≤1%; NLF: Occurred >48 hours after injection, duration ranged from 3 weeks to >3 months), skin rash (NLF and acne scars: ≤1%)
Hypersensitivity: Hyperesthesia (NLF: 2%; duration ranged from 4 weeks to unresolved at 26 weeks)
Local: Residual mass at injection site (NLF: 5% [1 month postinjection; duration ranged from 4 weeks to unresolved at 26 weeks], acne scars: <1% [many patients reported residual lumps/bumps up to 2 weeks postinjection]), injection site reaction (4%), tenderness at injection site (acne scars: 4%, NLF: <1% [occasional]), erythema at injection site (NLF: ≤4% [duration ranged from 5 weeks to unresolved at 26 weeks], acne scars: <1% [many patients reported erythema up to 2 weeks postinjection]), swelling at injection site (NLF and acne scars: ≤4%; NLF: duration ranged from 5 weeks to unresolved at 26 weeks), bruising at injection site (2%; many patients reported bruising up to 2 weeks postimplantation), pain at injection site (2%)
Neuromuscular & skeletal: Arthralgia (1%)
Respiratory: Nasopharyngitis (3%), sinusitis (1%)
<1%, postmarketing, and/or case reports: Abscess, acneiform eruption, acne vulgaris, actinic keratosis, areata alopecia (NLF; some occurrences reported ≥3 months after injection), atopic dermatitis, bacterial infection, blurred vision, burning sensation, chest congestion (mild), cutaneous papilloma, exacerbation of herpes labialis, flu-like symptoms, granuloma (NLF; duration ranged from 10 weeks to unresolved at 26 weeks), herpes zoster, hordeolum, implant-site complication (NLF; enlargement of implant; duration ranged from 10 weeks to unresolved at 26 weeks), influenza, limb pain, meningitis, otic infection, pharyngitis, puncture wound (NLF; puncture area visible; duration 13 weeks), seborrheic dermatitis, skin discoloration at injection site, squamous cell carcinoma of skin, syncope, telangiectasia (NLF; occasional, some occurrences reported ≥3 months postinjection), xeroderma
Hypersensitivity to polymethylmethacrylate, lidocaine, bovine collagen, or any component of the formulation; positive response to Bellafill Skin test; patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients undergoing or planning to undergo desensitization injections to meat products; patients with bleeding disorders; patients with susceptibility to keloid formation or hypertrophic scarring; use for lip augmentation and injection into the vermilion or the wet mucosa of the lip.
Concerns related to adverse effects:
• Intravascular injection: Inadvertent intravascular injection of dermal fillers may cause embolization, vessel occlusion, ischemia, or infarction resulting in vision impairment or blindness, cerebral hemorrhage or ischemia, skin necrosis, and damage to underlying facial structures. Treatment should be discontinued and patient promptly evaluated if exhibiting any signs or symptoms of intravascular injection.
• Skin effects: Hyperpigmentation, keloid formation, or hypertrophic scars may occur after dermal filler injections.
Disease-related concerns:
• Acne scars: Safety and effectiveness have not been established in patients with non-distensible atrophic acne scars, ice pick scars, or sinus tract scars.
• Connective tissue disorder: Safety has not been established in patients with connective tissue disorder. Use with caution; may have increased hypersensitivity response and/or accelerated clearance of implants. Further skin testing may be necessary.
Concurrent drug therapy issues:
• Anticoagulant/antiplatelet agents: Use within 3 weeks after administration has not been studied.
• Immunosuppressive therapy: Concomitant use with immunosuppressive therapy has not been established. Use with caution; may have increased hypersensitivity response and/or accelerated clearance of implants. Further skin testing may be necessary.
• Other dermal response procedures: Laser treatment, chemical peeling, or similar procedures may elicit an inflammatory response at injection site.
• Other wrinkle therapies: Use within 6 months of other wrinkle therapies (eg, collagen, botulinum toxin) has not been studied.
Other warnings/precautions:
• Appropriate administration: Dermal fillers, including polymethylmethacrylate, should be administered using a syringe with a needle or cannula. Needle-free devices for injection of dermal fillers are not FDA-approved and may cause serious injuries or permanent harm to the skin, lips, or eyes. FDA-approved dermal fillers should not be transferred into needle-free injection devices (FDA Safety Communication 2021).
• Appropriate use: Not indicated for use in the periocular area; granulomas, lumps, swelling, and vision loss due to vascular occlusion have been reported with off-label injection into the periocular area.
• Cold weather: Exposure to extreme cold weather should be minimized until initial swelling and redness have resolved.
• Photosensitivity: Excessive exposure to sun or UV lamp should be minimized until initial swelling and redness have resolved.
• Skin inflammation or infection: Treatment should be deferred if active inflammation (eg, cysts, pimples, rash, hives) or infection present at injection site(s).
• Skin testing: Skin testing must be performed; patients with a positive test, two equivocal tests, or demonstrating an anti-bovine collagen serum IgG level outside the normal range at baseline should not be treated.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Implant, dermal:
Bellafill: Polymethylmethacrylate microspheres 20% and lidocaine 0.3% [contains bovine collagen]
Bring syringe to room temperature before injection. Injection area should be washed with soap and water then cleaned with alcohol or other antiseptic. Refer to manufacturer's instructions for use for comprehensive administration information.
Nasolabial folds and facial acne scars : Correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients 21 years and older.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Corticosteroids (Systemic): May enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification
COVID-19 Vaccine (mRNA): May enhance the adverse/toxic effect of Dermal Fillers. Specifically, the risk for swelling at or near the site of dermal filler injection (usually face or lips) may be increased. Risk C: Monitor therapy
Immunosuppressants (Cytotoxic Chemotherapy): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification
Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification
Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification
Methotrexate: May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving methotrexate. Consider use of additional skin tests prior to administration. Risk D: Consider therapy modification
Women of reproductive potential not using effective contraception were excluded from initial studies (Cohen 2004; Joseph 2015).
Pregnant women were excluded from initial studies (Cohen 2004; Joseph 2015).
Breastfeeding women were excluded from initial studies (Cohen 2004; Joseph 2015).
After implantation, the bovine collagen component dissipates over the course of 1 to 3 months, leaving behind the nonbiodegradable PMMA microspheres. The microspheres stimulate a local inflammatory reaction that is followed by the deposition of granulation tissue during the first few weeks after implantation. The connective tissue subsequently matures, and by three months after injection, PMMA microspheres are surrounded by newly formed collagen. The presence of new collagen accounts for the observed volume-filling effect (Cohen 2004; Lemperle 2010).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
